Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or Surgically Unresectable Uterine or Soft Tissue Leiomyosarcoma
Fundings from the LMS04 study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1548 results
FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Evidence for efficacy is based on the results from the PERSEUS study
Six Years of Adjuvant Imatinib Improves DFS Over Three Years Treatment in Patients with Localised GIST At High Risk of Relapse
Findings from the IMADGIST study
Tarlatamab Demonstrates Sustained Clinical Benefit and Potential Findings of Intracranial Activity in Patients with Previously Treated ES-SCLC
Findings from extended follow-up of the DeLLphi-300 study
FDA Approves Lazertinib with Amivantamab-vmjw for Locally Advanced or Metastatic NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Substitution Mutations
Evidence for efficacy is based on the results from the MARIPOSA study
Androgen Receptor Pathway Inhibitors Outperform Taxanes in Patients with mCRPC with Detectable ctDNA
Findings from the ProBio study
FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy
Evidence for efficacy is based on the results from the RUBY study
Potential of Molecular Profiling to Refine Surgical and Radiotherapy Decision-Making in Patients with Meningioma
Findings from the largest meningioma cohort including a prospective set from the RTOG-0539 study
EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin and Pembrolizumab
The combination is indicated for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy
Trastuzumab Deruxtecan Shows Promising Activity Among Patients with HER2-positive and Signal of Efficacy in HER2-low BTC
Findings from the HERB study
Belzutifan Shows a Significant Benefit Over Everolimus in Patients with Advanced Clear Cell RCC After Both ICI and Antiangiogenic Therapies
Findings from the LITESPARK-005 study
FDA Approves Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma with a Susceptible IDH1 or IDH2 Mutation
Evidence for efficacy is based on the results from the INDIGO study